Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Kidney Drug's hidden heart benefits under the microscope

NCT ID NCT05719714

First seen Apr 15, 2026 · Last updated Jun 18, 2026 · Updated 9 times

Summary

This study looks at how dapagliflozin, a diabetes drug, affects heart function and metabolism in people with chronic kidney disease. Researchers will measure heart strain, oxygen use during exercise, and blood chemicals in 60 adults. The goal is to understand how the drug works beyond its usual effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60607, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome diastolic heart failure heart failure kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.